Skip to main content

Table 1 Sample description and statistics for participants’ age and gender

From: Reduced pain perception in children and adolescents with ADHD is normalized by methylphenidate

Whole KiGGS samplea N = 13.488 (100 %)

Subsamples selected out of the whole KiGGS Sample by available information

MPH treatment sampleb N = 4637 (34.38 % of the whole KiGGS sample)

Pain perception samplec N = 2867 (61.83 % of the whole KiGGS sample)

Study sampled N = 260 (3.56 % of the whole KiGGS sample)

Participant Group

N = 260

(100 %)

 

HC

N = 12828

(95.1 %)

ADHD sample

N = 660

(4.9 %)

Whole KiGGS sample N = 13488 (100 %)

HC

N = 4370

(94.2 %)

ADHD without MPH

N = 182

(3.9 %)

ADHD with MPH

N = 85

(1.9 %)

Whole sample N = 13488

(100 %)

ADHD without MPH

N = 115

(4.01 %)

ADHD with MPH

N = 65

(2.27 %)

HC

N = 130

(50 %)

ADHD without MPH

N = 65

(25 %)

ADHD with MPH

N = 65

(25 %)

Participant age (years)

3–6 

3509

(27.4 %)

57

(8.6 %)

3566

(26.4 %)

956

(21.9 %)

15

(8.2 %)

–

3566

(26.4 %)

6

(5.22 %)

–

–

–

–

 

7–10 

3542

(27.6 %)

215

(32.6 %)

3757

(27.9 %)

1255

(28.7 %)

58

(31.9 %)

37

(43.5 %)

3757

(27.9 %)

40

(34.78 %)

31

(47.69 %)

61

(49.6 %)

31

(47.7 %)

31

(47.7 %)

123

(47.3 %)

11–13

2581

(20.1 %)

202

(30.6 %)

2783

(20.6 %)

942

(21.6 %)

45

(24.7 %)

29

(34.1 %)

2783

(20.6 %)

27

(23.48 %)

19

(30.77 %)

41

(31.5 %)

22

(33.8 %)

19

(29.2 %)

82

(31.5 %)

14–17 

3196

(24.9 %)

186

(28.2 %)

3382

(25.1 %)

1217

(27.8 %)

64

(35.2 %)

19

(22.4 %)

3382

(25.1 %)

42

(36.52 %)

15

(21.54 %)

28

(21.5 %)

12

(18.5 %)

15

(23.1 %)

55

(21.2 %)

Group difference

χ2 = 124.86, df = 3, p < 0.001

 

χ2 = 31.20, df = 3, p < 0.001

χ2 = 31.30, df = 3, p < 0.001

χ2 = 0.573, df = 4, p = 0.966

 

Gender

Male

527

(79.8 %)

6224

(48.5 %)

6751

(50.1 %)

71

(83.5 %)

143

(78.6 %)

71

(83.5 %)

6751

(50.1 %)

91

(79.13 %)

51

(78.5 %)

86

(66.2 %)

47

(72.3 %)

51

(78.5 %)

184

(70.8 %)

Female

6604

(51.5 %)

133

(20.2 %)

6737

(49.9 %)

14

(16.5 %)

39

(21.4 %)

14

(16.5 %)

6737

(49.9 %)

24

(20.87 %)

14

(21.5 %)

44

(33.8 %)

18

(27.7 %)

14

(21.5 %)

76

(29.2 %)

Group difference

χ2 = 246.45, df = 1, p < 0.001

 

χ2 = 38.07, df = 1, p < 0.001

χ2 = 23.63, df = 3, p < 0.001

χ2 = 3.27, df = 2, p 0.195

 
  1. MPH methylphenidate; ADHD attention deficit hyperactivity disorder
  2. aWhole KiGGS Sample, represents the whole KiGGS sample (without missing data) regarding the classification ADHD diagnosis yes/no
  3. bMPH Treatment Sample, includes only those participants out of the whole KiGGS Sample with available information regarding ADHD diagnosis and MPH medication
  4. cPain Perception Sample, includes only those participants out of the whole KiGGS Sample with available information regarding ADHD diagnosis, MPH treatment and information about pain perception
  5. dStudy Sample includes 65 participants, who confirmed to have ADHD, to take MPH and to have had pain during the last three months according to ratings in the Pain Perception Sample. In addition, an ADHD group (n = 65) without MPH medication and a HC group (n = 2 × 65 = 130) randomly have been selected out of the Pain Perception Sample to minimize/rule out that the homogeneity of variance assumption is affected. The three participant groups (ADHD with MPH, ADHD without MPH, HC) of the study sample do not differ with respect to age- or gender (all p > 0.195)
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000